Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 20/20 | 0.98 |
| ▸ | CDK6 known ✓ | Q00534 | 1/20 | 0.75 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.75 |
| ▸ | PARP3 | Q9Y6F1 | 2/20 | 0.91 |
| ▸ | TNKS | O95271 | 1/20 | 0.75 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.75 |
| ▸ | PARP6 | Q2NL67 | 1/20 | 0.75 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.75 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.75 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.75 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.75 |
| ▸ | PARP8 | Q8N3A8 | 1/20 | 0.75 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.75 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.75 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.75 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.75 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.75 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22656793 | 1.00 | PARP1 (0.98) | PARP1PARP3TNKSADORA1CDK6 | |
| Hydrochloric Acid SCHEMBL23113141 | 1.00 | PARP1 (0.98) | PARP1PARP3TNKSADORA1CDK6 | |
| SCHEMBL29463415 | 0.99 | PARP1 (1.00) | PARP1PARP3TNKSADORA1CDK6 | |
| SCHEMBL30205023 | 0.99 | PARP1 (1.00) | PARP1PARP3TNKSADORA1CDK6 | |
| SCHEMBL524782 | 0.99 | PARP1 (1.00) | PARP1PARP3TNKSADORA1CDK6 | |
| SCHEMBL864319 | 0.95 | PARP1 (1.00) | PARP1PARP3 | |
| SCHEMBL29434944 | 0.95 | PARP1 (1.00) | PARP1PARP3 | |
| SCHEMBL19569971 | 0.93 | PARP1 (0.90) | PARP1PARP3TNKSADORA1CDK6 | |
| SCHEMBL17781907 | 0.92 | PARP1 (0.86) | PARP1PARP3TNKSADORA1CDK6 | |
| SCHEMBL30293115 | 0.91 | PARP1 (0.89) | PARP1PARP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116803990-A | Preparation method of Olaparib | 天津法莫西医药科技有限公司 | 2023-09-26 | — | — | CN | claimed |
| US-12398121-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-20240115711-A1 | Novel Bifunctional Molecules For Targeted Protein Degradation | AMPHISTA THERAPEUTICS LIMITED (GB) | 2024-04-11 | — | — | US | disclosed |
| CN-113811333-B | Compounds targeting anti-cancer nuclear hormone receptors | 诺维逊生物股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-4263511-A1 | NOVEL BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | Amphista Therapeutics Ltd (GB) | 2023-10-25 | — | — | EP | disclosed |
| CN-116897150-A | Novel bifunctional molecules for protein-targeted degradation | 安菲斯塔治疗有限公司 | 2023-10-17 | — | — | CN | disclosed |
| CN-116803990-A | Preparation method of Olaparib | 天津法莫西医药科技有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-116803990-A | Preparation method of Olaparib | 天津法莫西医药科技有限公司 | 2023-09-26 | — | — | CN | disclosed |
| US-20230122310-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2023-04-20 | — | — | US | disclosed |
| WO-2022129925-A1 | NOVEL BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| EP-3969050-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12398121-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | PARP1 1873/4885CDK6 305/4885PDE3A 4591/4885 |
| US-20230122310-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | PARP1 1873/4885CDK6 305/4885PDE3A 4591/4885 |
| US-20240115711-A1 | Novel Bifunctional Molecules For Targeted Protein Degradation | PSMG3, MYCBP2, PSME2 | PARP1 1896/4885CDK6 2648/4885PDE3A 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.